In this study, we explored the prognostic role of BTK in CCRT-resistant cancer cells, and we hypothesized that BTK exhibits a strong positive correlation with the stemness regulator genes, and that ibrutinib, a first-in-class small molecule inhibitor of BTK, can be combined with cisplatin to effectively inhibit ALDH+ OSCC-CSCs. This evidence concerns the gene LDHA and cancer.